Login
Zymeworks Inc. logo

Zymeworks Inc.

zymeworks.com

What Do They Do?

Develops antibody medicines for cancer, inflammation and autoimmune disease, and licenses drug candidates to pharmaceutical partners.

How Do They Make Money?

Pharmaceutical partners pay for licenses and technology access upfront, milestone payments when development or regulatory targets are met, and royalties tied to product sales; they also pay for research and development work as it is performed.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical partners receive licenses to develop and commercialize drug candidates. BeOne handles zanidatamab commercial activity in Asia excluding Japan, Australia and New Zealand, while Jazz handles commercial activity in its territory; Zymeworks does not plan to market candidates itself.

Do Revenues Turn Into Profits?

No. It lost $81.1M in FY2025.

Operating income, FY2025
−87% of revenue
▲ +33% (Loss) vs FY2024 (−$137.1M, −180%)
Net income, FY2025
−77% of revenue
▲ +34% (Loss) vs FY2024 (−$122.7M, −161%)
Free cash flow, FY2025
−33% of revenue
▲ +69% (Loss) vs FY2024 (−$112M, −147%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +829%
vs $27.6M in Q3 FY2025
Net income
▲ Turned profitable
vs −$19.6M in Q3 FY2025
  • Nov 9, 2026 Raised 2026 revenue and adjusted EBITDA guidance Revenue guidance increased to $337 million to $351 million from $278 million to $292 million.
  • Oct 22, 2026 Agreed to license ZW209 worldwide to Roche Roche will fund later development and commercialization; Zymeworks is eligible for upfront, milestone and sales-based royalty payments.
  • Sep 23, 2026 Completed acquisition of Theravance Biopharma The acquisition adds YUPELRI and other commercial, royalty and milestone assets to Zymeworks' portfolio.
  • Aug 25, 2026 Ziihera received U.S. approval for first-line GEA treatment The approval earned a $250 million milestone from Jazz and expanded the drug's approved use.

From drug developer to asset portfolio manager The earlier report framed the business around discovering, developing and commercializing multifunctional biotherapeutics, led by a drug-candidate pipeline. The latest report centers on managing licensed assets and royalty streams through partnerships, while continuing internal research and development.

Who Do They Compete With?

Competes with F. Hoffmann-La Roche, Novartis Pharmaceuticals, Puma Biotechnology, AstraZeneca, Daiichi Sankyo, Seagen, MacroGenics, Jiangsu HengRui Medicine, Pfizer, Alphamab, BioNTech, Boehringer, Bayer, AbbVie, Genmab, Eli Lilly, Legend Biotech, Sotio, Akeso Bio, and Amgen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support